Neurooncology group, Biodonostia Institute, Paseo Dr. Beguiristain s/n, E-20014 San Sebastian, Spain.
Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):216-27. doi: 10.2174/15748928113089990002.
Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
胶质母细胞瘤是成人中最常见、侵袭性最强和致命性的脑肿瘤。然而，目前的治疗方案成功率较低，平均总生存期不到 15 个月。治疗耐药性在很大程度上是由于这种肿瘤具有显著的细胞和表型异质性。在肿瘤块中发现具有干细胞特性的细胞亚群，这对治疗具有深远的意义，因为越来越多的证据表明，这些细胞，即胶质母细胞瘤干细胞（GSCs），是胶质母细胞瘤起源、维持和复发的原因。这些发现强调了需要对 GSCs 进行特征描述，以便找到针对它们的新型治疗方法。在这篇综述中，我们总结了关于这个问题的最新知识，包括一些最近的相关专利。
